SCHEDULE 13D: Activist Investor BML Capital Pushes Elevation Oncology for Immediate Liquidation and Shareholder Cash Return

BML Investment Partners, holding a 9.9% stake in Elevation Oncology, has formally urged the company's Board of Directors to pursue an orderly winddown, liquidation, and return of capital to shareholders, citing unfavorable market conditions and poor performance of recent biopharma reverse mergers.

Summary

• BML Investment Partners, L.P., along with BML Capital Management, LLC and Braden M. Leonard (collectively "Reporting Persons"), has acquired 5,890,934 shares of Elevation Oncology, Inc. common stock, representing 9.9% of the outstanding shares.
• The shares were acquired for investment purposes using $1,711,725 of working capital.
• On April 16, 2025, BML sent a letter to Elevation Oncology's Board of Directors advocating for an orderly winddown of operations and a return of all remaining cash to shareholders.
• BML estimates distributable net-cash was approximately $0.80 per share as of March 31, and swift action could yield a cash return approaching $0.60 per share, without valuing the EO-1022 asset.
• BML explicitly stated it would oppose any reverse merger or other strategic deal that does not include a substantial return of cash to shareholders as a special dividend at closing.

Sentiment

Score: 3

Explanation: The sentiment is largely negative as a significant shareholder is advocating for the company's liquidation and return of capital, citing unfavorable market conditions and past failures of similar strategic moves. While the company's decision to discontinue a non-competitive drug is seen as positive by the activist, the overall proposal for winddown indicates a pessimistic outlook on the company's future as a going concern.

Positives

• Elevation Oncology's decision to discontinue development of EO-3021 is applauded by BML, as initial data was insufficient for a competitive risk-benefit profile.
• BML appreciates the company's swift actions taken to preserve cash while exploring strategic alternatives.

Negatives

• Initial data for Elevation Oncology's EO-3021 drug candidate was insufficient to provide a competitive risk-benefit profile compared to other ADCs in development, leading to its discontinuation.
• BML cites the "abysmal performance of several recent reverse mergers" in the biopharma sector as a reason to avoid such a path without a significant cash return.

Risks

• The current state of the public equity market is unfavorable.
• The biopharma sector specifically faces challenging conditions.
• There is a risk of abysmal performance from reverse mergers, as observed in recent examples.
• The company's EO-1022 asset is not assigned any value in BML's cash return estimate, implying potential uncertainty or low perceived value.

Future Outlook

BML Investment Partners explicitly states its intention to continuously evaluate Elevation Oncology's business, results, and prospects. The Reporting Persons reserve the right to acquire or dispose of additional securities and to formulate other plans regarding the Issuer. BML's primary forward-looking proposal is for an orderly winddown, liquidation, and return of capital to shareholders, and they intend to vote against any reverse merger or strategic deal that does not include a significant cash return.

Management Comments

• "I applaud the Company's decision to discontinue development of EO-3021 after initial data was insufficient to provide a competitive risk-benefit profile compared to other ADCs in development."
• "I also appreciate the swift actions taken to preserve cash while exploring strategic alternatives."
• "Given the current state of the public equity market and the biopharma sector specifically, along with the abysmal performance of several recent reverse mergers, I believe that the best course of action is a winddown of operations and a return of all remaining cash to shareholders."
• "I estimate that distributable net-cash was approximately $0.80 per share as of March 31 and that swift action could produce a cash return approaching $0.60 per share for shareholders, without assigning any value to EO-1022."
• "BML would not be in favor of a reverse merger unless it included a full return of cash as a special dividend at the close, and, as such, will vote against any reverse merger or other deal that doesn't include a large return of cash to shareholders."

Industry Context

This announcement highlights the challenging environment within the biopharma sector, particularly concerning the viability of drug development programs and the perceived risks associated with reverse mergers. BML's stance reflects a broader investor sentiment that, in certain market conditions, returning capital to shareholders via liquidation may be preferable to pursuing uncertain strategic alternatives, especially given the 'abysmal performance' of recent reverse mergers in the sector.

Comparison to Industry Standards

• The document does not provide specific comparable companies or projects.
• BML's assessment of "abysmal performance of several recent reverse mergers" suggests a negative comparison to general industry outcomes for such transactions, implying that Elevation Oncology should avoid a similar fate without significant shareholder protection.
• The decision to discontinue EO-3021 due to insufficient competitive risk-benefit profile indicates that the drug candidate did not meet the efficacy or safety standards required to compete effectively with other Antibody-Drug Conjugates (ADCs) in development within the biopharma industry.

Stakeholder Impact

• Shareholders: Potential for a cash return (estimated $0.60 per share) if BML's liquidation proposal is adopted, but also implies the cessation of the company's ongoing operations and potential loss of future growth opportunities. Shareholders will also be impacted by BML's voting stance on future strategic alternatives like reverse mergers.
• Employees: A winddown of operations would likely result in significant job losses.
• Customers/Partners: Discontinuation of drug development programs (like EO-3021) and potential liquidation would cease any ongoing or future relationships.
• Creditors: Liquidation would involve settling outstanding liabilities, potentially impacting creditors depending on the company's asset value.

Next Steps

• Elevation Oncology's Board of Directors to consider BML's proposal for an orderly winddown, liquidation, and capital return.
• BML Investment Partners will vote against any reverse merger or other strategic deal that does not include a full return of cash as a special dividend at closing.
• BML reserves the right to acquire or dispose of additional securities of Elevation Oncology.

Key Dates

Recommendation

Keywords

Elevation Oncology, BML Investment Partners, Schedule 13D, Activist Investor, Shareholder Activism, Liquidation, Capital Return, Biopharma, Reverse Merger, SEC Filing, Shareholder Value, EO-3021, EO-1022